“The vote of the United States to remove cannabis and cannabis resin from the Schedule IV of the Single Convention while retaining them in Schedule I is consistent with the science demonstrating that while a safe and effective cannabis-derived therapeutic has been developed, cannabis itself continues to pose significant risks to public health and should continue to be controlled under the international drug control conventions,” said the US delegation in a release.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…